Gujarat Themis Biosyn QIP at ₹354 raises ₹75 cr in 2026

QIP closes after three-day window

Gujarat Themis Biosyn has closed its qualified institutional placement (QIP) with the issue price fixed at ₹354 per equity share. The company said its Fund-Raising Committee approved the closure on August 28, 2026. The QIP had opened on August 25, 2026. The allotment was made to eligible qualified institutional buyers (QIBs) through a total issue size of ₹75 crore. The placement is a key capital-raising step that follows shareholder authorisation earlier in August. The company is engaged in manufacturing and marketing bulk drugs and intermediates, with a focus on fermentation-based APIs used in anti-tuberculosis and antibiotic products.

Issue price, discount, and SEBI ICDR compliance

The final issue price of ₹354 per share was set at a discount to the floor price that the board had previously announced. The company’s board had fixed the floor price at ₹372.57 per equity share at its meeting on August 25, 2026. The final issue price reflects a discount of ₹18.57 per share, which is 4.98% below the floor price. Gujarat Themis Biosyn linked this to Regulation 176(1) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Under these rules, and based on shareholder approval, the issuer can offer up to a 5% discount on the floor price. The company stated the discount applied is within the maximum permitted 5%.

Share allotment details and total proceeds

As per the regulatory disclosure, the Fund-Raising Committee allotted 2,11,86,440 equity shares to QIBs. The total proceeds from the QIP were ₹75 crore. The company also disclosed that the issue price includes a premium of ₹353 over the face value of ₹1 per share. One of the notable allocation points disclosed was that Quant Small Cap Fund emerged as the largest single allottee, holding a 25.67% stake among the QIP allottees referenced in the summary. The company’s disclosures framed the QIP as a completed institutional capital raise, with pricing, allotment, and compliance steps formally approved and communicated.

How shareholder approval shaped the fund-raise

The company indicated that shareholders had approved the fund-raising measure with 99.97% support via postal ballot. In a broader context mentioned in the provided material, shareholders voted on three special resolutions between July 24 and August 22, with support ranging from 99.97% to 99.99% in favour. These approvals provided the company a formal route to raise up to ₹1,000 crore through a QIP and up to ₹1,500 crore through non-convertible debentures (NCDs). The QIP that has now closed represents the executed portion of that wider fund-raising authorisation.

Equity capital expands after the QIP

Following the allotment, Gujarat Themis Biosyn reported a rise in its paid-up equity share capital. Paid-up capital increased from ₹10.90 crore (10,89,65,265 shares) to ₹13.02 crore (13,01,51,705 shares). This reflects the issuance of new shares under the QIP. The updated paid-up capital number is important for investors tracking dilution, post-issue share count, and changes in ownership due to institutional allotments. The company’s filing presented both the rupee value of paid-up capital and the corresponding number of shares outstanding.

Trading window closure and compliance actions

The company reiterated that the trading window for dealing in Gujarat Themis Biosyn securities remains closed for designated persons under its internal code. This closure began on August 25, 2026. The restriction is set to remain until 48 hours after the determination of the final issue price. The same restriction was also referenced under the SEBI (Prohibition of Insider Trading) Regulations, 2015 framework, as described in the provided material. Such trading window closures are typically used to manage information sensitivity during corporate actions like fund-raising and price discovery.

Timeline: opening to closure

The QIP timeline was clearly stated. The issue opened on August 25, 2026, with the board setting the floor price on the same date. The Fund-Raising Committee then approved the closure and final pricing on August 28, 2026. The relevant date for the pricing calculation under the SEBI ICDR framework was also stated as August 25, 2026. This sequence matters because the floor price and the permissible discount depend on the regulatory formula and the relevant date.

Market prices cited around the QIP period

Several market price points were cited in the provided information across dates and times. On August 28, 2026 (11:34), the stock was indicated at ₹408.95 in pre-open, down 3.25 points (0.79%), with a bid-ask of 409.15 / 409.75. Another data point referenced the stock at ₹411.05 on August 28, 2026. Earlier, on August 26, 2026 at 14:09, the shares were reported at ₹420.10 on the NSE, up 3.79% for the day after opening at ₹401.75 against a previous close of ₹404.70. A separate reference cited the share price at ₹424.55 per share. These figures reflect reported market levels during the fund-raising window and related news flow.

Why the QIP pricing matters for investors

The QIP pricing shows how the company used the regulatory headroom for discounting. With a floor price of ₹372.57 and an allowed maximum discount of 5%, the final discount of 4.98% effectively used most of the permissible range. For investors, this highlights the balance between attracting institutional demand and limiting dilution from issuing shares below prevailing market levels. The post-allotment increase in paid-up capital also provides a clear reference point for updated share count. And the disclosure of a prominent allottee and the voting outcome gives additional context on participation and governance steps that supported the fund-raise.

Conclusion

Gujarat Themis Biosyn has completed its QIP by finalising an issue price of ₹354 per share, allotting 2.12 crore shares to QIBs and raising ₹75 crore. The company has also reported the resulting increase in paid-up equity capital to ₹13.02 crore. The trading window closure for designated persons remains in force from August 25, 2026 until 48 hours after final issue price determination, as stated in the disclosures. Further updates, if any, would typically come through exchange filings on allotment, share credit, and post-issue shareholding patterns.